FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to hepatology and diabetology, and can be used for treating non-alcoholic fatty liver disease combined with type 2 diabetes mellitus. A method involves a drug therapy. Content of retinol-binding protein and glycated hemoglobin in blood is pre-determined. If the level of retinol-binding protein is 152.1–220.3 mcg/l and the content of glycated hemoglobin is 8.1–8.5 %, alirocumab is administered in dose of 50–75 mg weekly for 4 weeks.
EFFECT: method provides higher clinical effectiveness in non-alcoholic fatty liver disease and type 2 diabetes mellitus by preliminary diagnosis and drug therapy with alirocumab.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR HEPATIC STEATOSIS AND STEATOHEPATITIS | 2013 |
|
RU2545990C2 |
| METHOD FOR DETERMINING RISK OF ISCHEMIC HEART DISEASE | 2013 |
|
RU2532361C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE | 2013 |
|
RU2537229C1 |
| METHOD FOR DIAGNOSING HEPATIC FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE WITH TYPE 2 DIABETES MELLITUS | 2019 |
|
RU2732526C1 |
| METHOD OF LACTASE DEFICIENCY IN ADULTS TREATMENT | 2017 |
|
RU2684099C1 |
| DIAGNOSTIC TECHNIQUE FOR DRUG-INDUCED LIVER INJURY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2695021C1 |
| METHOD OF DIAGNOSTICS OF LIVER STEATOSIS | 2017 |
|
RU2648183C1 |
| DIAGNOSTIC TECHNIQUE FOR ASYMPTOMATIC CELIAC DISEASE IN ADULTS | 2020 |
|
RU2747523C1 |
| METHOD OF THE TREATMENT OF POLYNEUROPATHY ASSOCIATED WITH GLUTEN-SENSITIVE CELIAC DISEASE | 2022 |
|
RU2800847C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE | 2011 |
|
RU2473342C1 |
